BSEM
BioStem Technologies, Inc.
There isn't enough reported data to score BSEM yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
BSEM Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Unavailable | |
| Strong |
BSEM's balance sheet is currently strong, but its revenue and profitability are under pressure. There isn't enough data to rate its cash flow.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
BSEM PE Valuation
BSEM has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
BSEM Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong decline | |
| Strongly weakening | |
| Limited | |
| High |
Analysts expect BSEM's losses to grow, with revenue declining.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over BSEM on the outlook, with more favorable earnings and revenue expectations.
BSEM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.35 | -387% |
| Q2 2026 | -$1.68 | -251% |
| Q1 2026 | -$1.18 | -183% |
| Q4 2025 | -$0.49 | -134% |
| Q3 2025 | $0.82 | +34% |
| Q2 2025 | $1.11 | +247% |
| Q1 2025 | $1.43 | +$1.63 |
| Q4 2024 | $1.43 | +$1.94 |
BSEM has swung to a loss: it lost $2.35 per share over the past year, after a profit the year before.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over BSEM on earnings quality, reporting a profit while its opponent remains loss making.
BSEM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $7.6M | -27% |
| Q2 2026 | $7.9M | -84% |
| Q1 2026 | $6.1M | -92% |
| Q3 2025 | $10.5M | -87% |
| Q2 2025 | $49.3M | -34% |
| Q1 2025 | $72.5M | +73% |
| Q4 2024 | $102.9M | +799% |
| Q3 2024 | $82.6M | +2194% |
BSEM's revenue has slid since its 2024 peak: $8M last quarter, down 27% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -128% | -142 points |
| Q2 2026 | -106% | -107 points |
| Q1 2026 | -145% | -152 points |
| Q3 2025 | 14% | +2.6 points |
| Q2 2025 | 0.2% | -12 points |
| Q1 2025 | 7.2% | -3.8 points |
| Q4 2024 | 8.2% | +33 points |
| Q3 2024 | 11% | -3.5 points |
BSEM's operating margin was −128% last quarter, down 128 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over BSEM on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over BSEM on profitability, with a higher operating margin.
BSEM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$8.8M | -$4M |
| Q1 2026 | -$827.3K | -121% |
| Q4 2025 | $2.4M | -70% |
| Q3 2025 | -$4.8M | -152% |
| Q2 2025 | $5.1M | -18% |
| Q1 2025 | $3.9M | +622% |
| Q4 2024 | $8M | +$9.4M |
| Q3 2024 | $9.3M | +$9.8M |
LLY has the stronger cash trend. Its trailing FCF is up 259% versus its history, compared with BSEM at down 371%.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
BSEM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.1% | +537K shares |
| 1 year | -23% | -5.4M shares |
| 3 years | +32% | +4.4M shares |
| 5 years | +93% | +8.6M shares |
| Available history | +94% | +8.7M shares |
BSEM has the edge over LLY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | $1.00 |
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has 893M diluted shares, down 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
BSEM Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2025 | -1.5x | Net Cash |
| Q2 2025 | -1.2x | Net Cash |
| Q1 2025 | -0.7x | Net Cash |
| Q4 2024 | -0.6x | Net Cash |
| Q3 2024 | -0.5x | Net Cash |
| Q2 2024 | -0.2x | Net Cash |
| Q1 2024 | 19.3x | High |
BSEM has more cash than debt.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
BSEM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.3 | Neutral |
| Stochastic | 3.2 | Oversold |
BSEM's weekly RSI is 32 (neutral) and its Stochastic is 3 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
BSEM PE vs Healthcare Sector
| Metric | BSEM | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
BSEM has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
BSEM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.07 | 37% below |
| 20 week MA | $3.08 | 58% below |
| 50 week MA | $4.09 | 68% below |
| 100 week MA | $7.27 | 82% below |
| 200 week MA | $6.91 | 81% below |
BSEM is in a downtrend: it's below all five of its weekly moving averages, and 81% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over BSEM on trend strength, trading above more of its moving averages.
BSEM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $2.50 | $1.40 | -44% |
| 2021 | $1.40 | $1.10 | -21% |
| 2022 | $1.10 | $3.48 | +216% |
| 2023 | $3.48 | $5.86 | +68% |
| 2024 | $5.86 | $12.7 | +116% |
| 2025 | $12.7 | $3.87 | -69% |
| 2026 YTD | $3.87 | $1.30 | -66% |
BSEM's yearly returns have swung widely, from +216% in 2022 to −69% in 2025. It's down 66% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over BSEM on returns for 2026, with the stronger performance.